What PSA is
Prostate-specific antigen (PSA) is a protein produced by prostate cells. Levels reflect prostate volume, inflammation, and cellular activity. PSA is elevated by benign prostatic hyperplasia (BPH), prostatitis, ejaculation, vigorous exercise (cycling), prostate manipulation, and prostate cancer.
The expected initial rise
Untreated low T can suppress PSA. Restoring testosterone to normal range often produces a modest PSA rise, typically 0.2-0.5 ng/mL, over the first 3-6 months as the prostate "wakes up." This is expected and not concerning.
After this initial adjustment, PSA usually stabilizes for the long term. Many men show no further change.
The saturation model
The Morgentaler research established that prostate androgen receptors saturate at relatively low testosterone levels, around the bottom of the normal range. Above saturation, additional testosterone doesn't drive additional prostate growth. This is why physiologic TRT (700-900 ng/dL total T) doesn't accelerate prostate cancer development the way the older "any androgen feeds prostate cancer" model predicted.
The 2023 TRAVERSE trial and multiple meta-analyses confirmed: monitored TRT in men with documented hypogonadism does not increase prostate cancer incidence.
What's actually concerning
| Pattern | Action |
|---|---|
| PSA rise >0.75 ng/mL/year | Investigate (rapid velocity) |
| Absolute PSA >4 ng/mL | Investigate |
| PSA >3 ng/mL with abnormal DRE | Investigate |
| Sudden change in stable PSA | Repeat in 6 weeks |
| Family history of prostate cancer + any rise | Lower threshold for investigation |
| Modest 0.2-0.5 rise in first 6 months on TRT | Expected; continue monitoring |
Monitoring schedule
- Baseline (before TRT), for comparison
- Month 3, confirm stable
- Month 6, confirm stabilization
- Annually thereafter
- Add DRE per general men's health guidelines (typically annually after 50)
When to evaluate further
If PSA pattern triggers concern, the next steps typically include:
- Repeat PSA in 6 weeks (rule out transient causes)
- Free PSA % (lower percentage suggests cancer)
- 4Kscore or PHI test (refined risk stratification)
- Multiparametric prostate MRI
- Urology referral and possible biopsy
TRT is usually paused during evaluation but can be resumed if cancer is ruled out.
The clinical pearl: The historical "TRT causes prostate cancer" fear has been resolved by the saturation model and TRAVERSE-era data. Standard PSA monitoring on TRT catches the rare problems early, and the model is reassurance-supporting for most men.
Bottom line
PSA monitoring on TRT is straightforward: small initial rise expected, then stable. Modern data has resolved the major prostate cancer concerns. Standard quarterly-then-annual monitoring catches what needs catching. For most men on TRT with normal initial PSA, the long-term picture is reassuring.